Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine. - No Study Results Posted

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine. (LEU LEU)

This study is ongoing, but not recruiting participants.

Study NCT00058799 Information provided by Baylor College of Medicine

First Received: April 11, 2003 Last Updated: April 9, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)